

# Clinical Policy: Proton and Neutron Beam Therapies

Reference Number: LA.CP.MP.70

Date of Last Revision: 02/25

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

## Description

Proton beam therapy (PBT) is a form of external beam radiation therapy (EBRT) that utilizes protons (positively charged subatomic particles) to precisely target a specific tissue mass. Proton beams can penetrate deep into tissues to reach tumors, while delivering less radiation to surrounding tissues. This may make PBT more effective for inoperable tumors, or for those areas in which damage to healthy tissue would pose an unacceptable risk.

Neutron beam therapy (NBT) is a less widely available form of EBRT that utilizes neutrons. Its clinical use is very limited due to difficulties in the delivery of this treatment modality.

## Policy/Criteria

- I. It is the policy of Louisiana Healthcare Connections that proton beam therapy (PBT) is **medically necessary** for the following indications:
  - A. Ocular tumors, including but not limited to, intraocular melanomas;
  - B. Primary spine or spinal cord tumors or metastatic tumors of the spine or spinal cord for which organ-at-risk tolerance may be exceeded with photon treatments;
  - C. Tumors that approach or are located at the base of the skull, including but not limited to, chordoma or chondrosarcoma;
  - D. Hepatocellular cancer and intra-hepatic biliary cancers;
  - E. Primary or benign solid tumors or other hematologic malignancies in members/enrollees  $\leq 21$  years old;
  - F. Tumors/cancers that can be treated with any other type of radiation in members/enrollees with a known genetic mutation/syndrome increasing the risk of cancer;
  - G. Malignant and benign primary CNS tumors, excluding IDH wild-type glioblastoma (GBM);
  - H. Pituitary neoplasms;
  - I. Advanced staged and unresectable head and neck cancers;
  - J. Cancers of the nasopharynx, nasal cavity, paranasal sinuses and other accessory sinuses, when normal tissue constraints cannot be met by photon-based therapy;
  - K. Non-metastatic retroperitoneal sarcomas;
  - L. Re-irradiation cases where cumulative critical structure dose would exceed tolerance dose;
  - M. Primary tumors of the mediastinum, including thymic tumors (i.e. thymoma, thymic carcinoma), mediastinal tumors and mediastinal lymphomas (i.e. Hodgkin lymphoma and Non-Hodgkin lymphoma), and thoracic sarcomas;
  - N. Non-small cell lung cancer, to spare critical structures when critical organ dose constraints cannot be met with photon therapy (including three dimensional and IMRT neutron techniques);
  - O. Malignant pleural mesothelioma;
  - P. Primary malignant or benign bone tumors;

- Q. Medically inoperable patients with a diagnosis of cancer typically treated with surgery where dose escalation is required due to the inability to receive surgery;
- R. Primary and metastatic tumors requiring craniospinal irradiation;
- S. Primary cancers of the esophagus;
- T. Advanced and unresectable pelvic tumors with significant pelvic and/or peri-aortic nodal disease;
- U. Members/enrollees with a single kidney or transplanted pelvic kidney with treatment of an adjacent target volume and in whom maximal avoidance of the organ is critical.
- V. Salivary gland tumors.

**II.** It is the policy of Louisiana Healthcare Connections that neutron beam therapy (NBT) is **medically necessary** in the treatment of salivary gland tumors when meeting any of the following:

- A. The tumor is considered surgically unresectable, recurrent, or is resected with gross residual disease or positive margins;
- B. Member/enrollee is medically inoperable.

**III.** It is the policy of Louisiana Healthcare Connections that all other indications for PBT and NBT are considered **not medically necessary** as insufficient evidence exists to recommend proton and/or neutron beam therapy as superior to other treatments available.

### **Background**

Proton beam therapy (PBT) is an important method of treatment used in managing malignant disease with a well-defined target. Unlike x-rays, protons cause little damage to the tissues they pass through to reach their destination. Their energy is released after traveling a specified distance, thus delivering more radiation to the tumor and doing less damage to the nearby normal tissue. Because of this, PBT may be more useful for tumors with distinct edges rather than those whose edges are mixed with normal tissue.

Radiation therapy (RT) plays a critical role in the local tumor control of benign and low-grade central nervous system tumors in children but is not without the risk of long-term treatment-related sequelae. PBT is an advanced RT modality with a unique dose-deposition pattern that allows for treatment of a target volume with reduced scatter dose delivered to normal tissues compared with conventional photon RT and is now increasingly utilized in children with the hope of mitigating radiation-induced late effects.<sup>1</sup>

The American Society of Radiation Oncology (ASTRO) evaluated the evidence of use of PBT and listed examples of indications for coverage of PBT in their 2023 Model Policy for PBT, which includes, but is not limited to the following:

1. The target volume is near one or more critical structures and a steep dose gradient outside the target must be achieved to avoid exceeding the tolerance dose to the critical structure(s), which would portend a higher risk of toxicity.
2. A proton-based technique would decrease the probability of clinically meaningful normal tissue toxicity by lowering an integral dose-based metric and/or organ at risk dose volume constraint associated with toxicity.

3. The same or an immediately adjacent area has been previously irradiated, and the dose distribution within the patient must be sculpted to avoid exceeding the cumulative tolerance dose of nearby normal tissue.<sup>2(p.3)</sup>

ASTRO states there is a need for continued clinical evidence development and comparative effectiveness analyses for the appropriate use of PBT for various disease sites and as such all other indications are suitable for Coverage with Evidence Development (CED). They note that radiation therapy for patients treated under the CED paradigm should be covered by the insurance carrier as long as the patient is enrolled either in an IRB-approved clinical trial or in a multi-institutional patient registry adhering to Medicare requirements for CED.<sup>2</sup>

### **Head and Neck Cancer**

Guidelines from National Comprehensive Cancer Network (NCCN) regarding PBT in the treatment of head and neck cancer state the following. “Achieving highly conformal dose distributions is especially important for patients whose primary tumors are periocular in location and/or invade the orbit, skull base, and/or cavernous sinus; extend intracranially or exhibit extensive perineural invasion; and who are being treated with curative intent and/or who have long life expectancies following treatment. Non-randomized single institution clinical reports and systematic comparisons demonstrate safety and efficacy of PBT in the above-mentioned specific clinical scenarios. Proton therapy can be considered when normal tissue constraints cannot be met by photon-based therapies, or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes.”<sup>3(p2)</sup>

### **Central Nervous System Cancers**

NCCN guidelines note that it is reasonable to consider proton beam therapy for craniospinal irradiation where available, as it is associated with less toxicity.<sup>4</sup>

### **Uveal Melanoma**

Per NCCN guidelines on uveal melanoma, “Tumor localization for proton beam therapy may be performed using indirect ophthalmoscopy, transillumination, and/or ultrasound (intraoperative or postoperative but before proton beam), x-ray, MRI and/or CT.”<sup>5(p2)</sup>

A practice parameter on PBT from the American College of Radiology/ASTRO also notes that “commonly, the ophthalmologist will guide patient selection with tumor/target definition through techniques such as funduscopic examination, fluorescein angiogram, ultrasound, and direct tumor measurements intraoperatively. Most commonly but not imperatively, radio-opaque fiducial markers are sutured to the sclera and used as references for tumor definition. Treatment planning for ocular tumors has been most frequently performed with a treatment planning algorithm and software system developed specifically for treatment of ocular tumors. Other alternative approaches have been devised when special eye line is not available.”<sup>6</sup>

### **Non-metastatic Retroperitoneal Sarcomas**

Per NCCN guidelines on soft tissue sarcoma (STS), surgical resection of a localized tumor with negative margins is the standard, potentially curative treatment for patients with retroperitoneal/intra-abdominal STS. Radiation therapy (RT) can be administered as preoperative treatment for patients with resectable disease or as a primary treatment for those with

unresectable disease. Post-operative RT is discouraged but may be considered in rare instances. Newer RT techniques such as IMRT and 3D conformal RT using protons or photons may allow tumor target coverage and acceptable clinical outcomes within normal tissue dose constraints to adjacent organs at risk. When EBRT is used, sophisticated treatment planning with IMRT, tomotherapy and/or proton therapy can be used to improve therapeutic effect. However, the safety and efficacy of adjuvant RT techniques have yet to be evaluated in a multicenter RCT. RT is not a substitute to definitive surgical resection with negative margins, and re-resection to negative margins is preferable.<sup>7</sup>

### **Hepatocellular Cancer**

Per NCCN guidelines on hepatocellular carcinoma (HCC), EBRT is a treatment option for patients with unresectable disease, or for those who are medically inoperable due to comorbidity. All tumors irrespective of the location may be amenable to RT [3D conformal RT, IMRT, and stereotactic Body Radiation therapy (SBRT)]. Image-guided radiotherapy is strongly recommended when using EBRT, IMRT, and SBRT to improve treatment accuracy and reduce treatment-related toxicity. Hypofractionation with photons or protons is an acceptable option for intrahepatic tumors, though treatment at centers with experience is recommended. PBT may be appropriate in specific situations.<sup>8</sup> In a phase II study, 94.8% of patients with unresectable HCC who received high dose hypofractionated PBT demonstrated >80% local control after two years, as defined by RECIST criteria.<sup>9</sup> Several ongoing studies are continuing to investigate the impact of hypofractionated PBT on HCC outcomes, including randomized trials comparing PBT to radiofrequency ablation (RFA). Data has demonstrated that local control is exceptional regardless of the fractionation used.<sup>10</sup> In a phase III study using the Child-Pugh classification, an evaluation of clinical outcomes of PBT versus RFA demonstrated PBT could be applied safely in patients with small recurrent hepatocellular carcinoma. The two-year local progression-free survival (LPFS) rate was 94.8% versus 83.2% respectively, demonstrating that PBT is not inferior to RFA treatment.<sup>11</sup>

### **Prostate Cancer**

ASTRO recommends coverage of PBT for the treatment of non-metastatic prostate cancer when enrolled in an institutional review board (IRB)–approved study or a multi-institutional registry that adheres to Medicare requirements for Coverage with Evidence Development (CED).<sup>2</sup> NCCN guidelines note that there lacks clear evidence to support a benefit or decrement to proton therapy over IMRT for either treatment efficacy or long-term toxicity. Firm conclusions regarding differences in toxicity or effectiveness of proton and photon therapy cannot be drawn because of the limitations of the available studies.<sup>12</sup>

### **Thymomas and Thymic Carcinomas**

Per NCCN, PBT has been shown to improve dosimetry compared to IMRT allowing better sparing of the normal organs (lungs, heart, and esophagus). Additionally, favorable results in terms of both local control and toxicity have been obtained with PBT. Based on these data, PBT is considered an appropriate treatment option.<sup>13</sup>

### **Hodgkin Lymphoma**

Per NCCN, “Treatment with photons, electrons or protons may all be appropriate, depending on clinical circumstances. Advanced RT technologies such as intensity-modulated RT

(IMRT)/volumetric modulated arc therapy (VMAT), deep-inspiratory breath hold (DIBH) or respiratory gating, image-guided RT (IGRT), and proton therapy may offer significant and clinically relevant advantages in specific instances to spare important normal OARs and decrease the risk for late, normal tissue damage while still achieving the primary goal of local tumor control.”<sup>14(p1)</sup>

### **Esophageal and Esophagogastric Junction Cancers**

NCCN guidelines indicate this emerging technique may offer protection of normal tissue by limiting exposure of adjacent organs to radiation in addition to lowering the rates of post-operative pulmonary, cardiac, gastrointestinal, and wound complications. The guidelines recommend that patients with esophageal cancer be treated with PBT within a clinical trial, noting that data is early and evolving.<sup>15</sup> An overall low-quality body of evidence suggests that PBT has possible benefit for the treatment of esophageal adenocarcinoma (EAC). PBT may have similar effectiveness to both IMRT and 3DCRT and results in significantly reduced radiation exposure to adjacent organs at risk. PBT could possibly result in fewer complications than IMRT (intensity-modulated radiation therapy) and 3DCRT (3-dimensional conformal radiation therapy) among patients undergoing esophagectomy, however the statistical significance of these findings was mixed. The rate of nonoperative complications was comparable between PBT and IMRT.<sup>16</sup> According to ASTRO’s 2023 Model Policy for PBT, published clinical data supports the use of PBT for primary cancers of the esophagus.<sup>2</sup>

### **Neutron Beam Therapy (NBT)**

NBT utilizes neutrons, rather than photons, to destroy tumor cells. Neutrons are much heavier than photons and appear to be more effective at causing damage to very dense tumors. It is however more clinically difficult to generate neutron particles, so it has not gained wide acceptance for treatment. It has most commonly been studied in salivary gland tumors which are either unable to be removed completely or for recurrent disease.

NCCN states NBT was historically considered a promising solution for unresectable salivary gland cancer, however, they no longer recommend NBT as a general solution for salivary gland cancers due to the diminishing demand, high rates of long-term toxicity over time, concerns regarding the methodologic robustness of available randomized trial data, and closure of all but one center in the U.S. The panel recognizes the potential clinical value of neutron therapy for select patients.<sup>3</sup>

### **Coding Implications**

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2023 American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only and may not support medical necessity. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

**CLINICAL POLICY**  
**Proton and Neutron Beam Therapies**



NOTE: Coverage is subject to each requested code's inclusion on the corresponding LDH fee schedule. Non-covered codes are denoted (\*) and are reviewed for Medical Necessity for members under 21 years of age on a per case basis.

CPT Codes	Description
77423	High energy neutron radiation treatment delivery, 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and/or wedge, and/or compensator(s)
77520	Proton treatment delivery; simple, without compensation
77522	Proton treatment delivery; simple, with compensation
77523	Proton treatment delivery; intermediate
77525	Proton treatment delivery; complex

HCPCS Codes	Description
S8030*	Scleral application of tantalum ring(s) for localization of lesions for proton beam therapy

Reviews, Revisions, and Approvals	Revision Date	Approval Date	Effective Date
Converted corporate to local policy.	11/2020		
Annual review. References reviewed and updated. Reviewed by specialist. Changed "Last Review Date" in the header to "Date of Last Review" and "Date" in revision log to "Revision Date". Added "may not support medical necessity" in coding implications. Replaced ICD-10 code C78.82 with C78.2. Updated background regarding PBT for benign and low-grade central nervous system tumors in children.	2/22	2/22	
Changed policy name to Therapies instead of Therapy. Removed "treated in a hypofractionated regimen" from I. D. Changed age to <21 in I. F. Added "and/or neutron" to criteria III. for clarity. Background updated and minor rewording with no clinical significance. Removed ICD-10 diagnosis code table. References reviewed, reformatted and updated.	1/23	4/3/23	
Annual review. Updated criteria I.G. to, unresectable benign or malignant central nervous system tumors to include but not limited to primary and variant forms of astrocytoma, glioblastoma, medulloblastoma, acoustic neuroma, craniopharyngioma, benign and atypical meningiomas, pineal gland tumors, and arteriovenous malformations. Added criteria I.H., Pituitary neoplasms. Restructured and added section A. and B. to criteria II. References reviewed and updated. Added note for non-covered codes.	1/24	3/25/24	



Reviews, Revisions, and Approvals	Revision Date	Approval Date	Effective Date
<p>Annual review. Minor rewording in Criteria I. Updated Criteria I.A. to include intraocular melanomas and removed language regarding fiducial markers. Added clarifying language to Criteria I.B. regarding primary spine or spinal cord tumors or metastatic tumors of the spine or spinal cord where organ at risk tolerance may be exceeded with photon treatments. Minor grammatical update to Criteria I.C. Updated Criteria I.D. by removing “Primary” and including intra-hepatic biliary cancers. Updated Criteria I.E. by adding “or other hematologic malignancies” and changing <math>\leq 18</math> years old to <math>\leq 21</math> years old. Updated verbiage in Criteria I.F. to state “Tumors/cancers that can be treated with any other type of radiation in members/enrollees with a known genetic mutation/syndrome.” Updated verbiage in Criteria I.G. to include malignant and benign primary CNS tumors, excluding IDH wild-type glioblastoma (GBM). Added clarifying language to Criteria I.J. and removed additional language regarding when normal tissue constraints cannot be met by photon-based therapy. Added cancers of the nasopharynx and nasal cavity to Criteria I.J. Removed “i.e., preoperative treatment of resectable disease or primary treatment for those with unresectable disease” in Criteria I.K. Combined previous Criteria I.N. regarding thymomas and thymic carcinoma with Criteria I.M. regarding primary tumors of the mediastinum. Added Criteria I.O. for malignant pleural mesothelioma. Added Criteria I.P. for primary malignant or benign bone tumors. Added Criteria I.Q. for medically inoperable patients with a diagnosis of cancer typically treated with surgery where dose escalation is required due to the inability to receive surgery. Added Criteria I.R. for primary and metastatic tumors requiring craniospinal irradiation. Added Criteria I.S. for primary cancers of the esophagus. Added Criteria I.T. for advanced and unresectable pelvic tumors with significant pelvic and/or peri-aortic nodal disease. Added Criteria I.U. for members/enrollees with a single kidney or transplanted pelvic kidney with treatment of an adjacent target volume and in whom maximal avoidance of the organ is critical. Added Criteria I.V. for salivary gland tumors. Minor verbiage update in Criteria II. with no impact to criteria. Background updated with no impact on criteria. References reviewed and updated. Reviewed by external specialist.</p>	2/25	4/28/25	5/29/25

## References

1. Eaton BR, Yock T. The use of proton therapy in the treatment of benign or low-grade pediatric brain tumors. *Cancer J*. 2014;20(6):403 to 408.  
doi:10.1097/PPO.0000000000000079
2. ASTRO Model Policies Proton Beam Therapy.  
<https://www.astro.org/ASTRO/media/ASTRO/Daily%20Practice/PDFs/ASTROPBTModelPolicy.pdf>. Published 2022. Accessed October 15, 2024.
3. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology. Head and neck cancers (Version 4.2024).  
[https://www.nccn.org/professionals/physician\\_gls/pdf/head-and-neck.pdf](https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf). Published May 01, 2024. Accessed October 14, 2024.
4. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology. Central nervous system cancers (Version 3.2024). [https://www.nccn.org/professionals/physician\\_gls/pdf/cns.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf). Published September 30, 2024. Accessed October 14, 2024.
5. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology. Melanoma: uveal (Version 1.2024).  
[https://www.nccn.org/professionals/physician\\_gls/pdf/uveal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf). Published May 23, 2024. Accessed October 16, 2024.
6. ACR-ARS practice parameter for the performance of proton beam radiation therapy.  
<https://www.acr.org/-/media/ACR/Files/Practice-Parameters/Proton-Therapy-RO.pdf>. Revised 2023. Accessed October 10, 2024.
7. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology. Soft tissue sarcoma (Version 3.2024).  
[https://www.nccn.org/professionals/physician\\_gls/pdf/sarcoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf). Published September 27, 2024. Accessed October 14, 2024.
8. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology. Hepatocellular carcinoma (Version 3.2024). [https://www.nccn.org/professionals/physician\\_gls/pdf/hepatobiliary.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf). Published September 24, 2024. Accessed October 14, 2024.
9. Hong TS, Wo JY, Yeap BY, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *J Clin Oncol*. 2016;34(5):460 to 468.  
doi:10.1200/JCO.2015.64.2710
10. Lewis S, Barry A, Hawkins MA. Hypofractionation in Hepatocellular Carcinoma - The Effect of Fractionation Size. *Clin Oncol (R Coll Radiol)*. 2022;34(5):e195 to e209.  
doi:10.1016/j.clon.2022.02.021
11. Kim TH, Koh YH, Kim BH, et al. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. *J Hepatol*. 2021;74(3):603 to 612. doi:10.1016/j.jhep.2020.09.026
12. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology. Prostate cancer (Version 4.2024).  
[https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf). Published May 17, 2024. Accessed October 16, 2024.



13. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology. Thymomas and thymic carcinomas (Version 1.2024).  
[https://www.nccn.org/professionals/physician\\_gls/pdf/thymic.pdf](https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf). Published November 21, 2023. Accessed October 15, 2024.
14. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology. Hodgkin lymphoma (Version 3.2024).  
[https://www.nccn.org/professionals/physician\\_gls/pdf/hodgkins.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf). Published March 18, 2024. Accessed October 15, 2024.
15. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology. Esophageal and esophagogastric junction cancers (Version 4.2024).  
[https://www.nccn.org/professionals/physician\\_gls/pdf/esophageal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf). Published July 30, 2024. Accessed October 15, 2024.
16. Zenonos GA. C. Chordoma of the skull base. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated August 01, 2024. Accessed October 11, 2024. Health technology assessment: Proton beam therapy for esophageal adenocarcinoma. Hayes. [www.hayesinc.com](http://www.hayesinc.com). Published October 21, 2022 (annual review November 29, 2023). Accessed October 10, 2024.
17. Aihara T, Morita N, Kamitani N, et al. Boron neutron capture therapy for advanced salivary gland carcinoma in head and neck. *Int J Clin Oncol*. 2014;19(3):437 to 444.  
doi:10.1007/s10147-013-0580-3
18. Allen AM, Pawlicki T, Dong L, et al. An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee. *Radiother Oncol*. 2012;103(1):8 to 11.  
doi:10.1016/j.radonc.2012.02.001
19. American Cancer Society. Radiation therapy for adult brain and spinal cord tumors.  
<https://www.cancer.org/cancer/brain-spinal-cord-tumors-adults/treating/radiation-therapy.html>. Updated May 16, 2023. Accessed October 10, 2024.
20. American Cancer Society. Radiation therapy for brain and spinal cord tumors in children.  
<https://www.cancer.org/cancer/brain-spinal-cord-tumors-children/treating/radiation-therapy.html>. Updated June 20, 2018. Accessed October 11, 2024.
21. Gewanter RM, Rosenzweig KE, Chang JY, et al. ACR appropriateness criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent. *Curr Probl Cancer*. 2010;34(3):228 to 249. doi:10.1016/j.currproblcancer.2010.04.001.
22. Kahalley LS, Okcu MF, Ris MD et al. IQ change within three years of radiation therapy in pediatric brain tumor patients treated with proton beam versus photon radiation therapy.  
[https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15\\_suppl.10009](https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.10009). Published May 20, 2013. Accessed October 11, 2024.
23. Karajannis MA, Marcus KJ. Focal brainstem glioma. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated September 24, 2024. Accessed October 11, 2024.
24. Maki RG. Radiation-associated sarcomas. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated June 01, 2023. Accessed October 11, 2024.
25. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology. B-cell lymphomas (Version 3.2024).  
[https://www.nccn.org/professionals/physician\\_gls/pdf/b-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf). Published August 26, 2024. Accessed October 17, 2024.
26. Korf BR, Lobbous M, Metrock LK. Neurofibromatosis type 1 (NF1): management and prognosis. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated October 04, 2024. Accessed October 11, 2024.

27. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology. Non-small cell lung cancer (Version 11.2024).  
[https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). Published October 15, 2024. Accessed October 17, 2024.
28. Lydiatt WM, Quivey JM. Salivary gland tumors: treatment of locoregional disease. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated December 20, 2023. Accessed October 11, 2024.
29. Bryant C, Smith TL, Henderson RH, et al. Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2016;95(1):422 to 434. doi:10.1016/j.ijrobp.2016.02.038
30. Harbour JW, Shih HA. Initial management of uveal and conjunctival melanomas. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated June 04, 2024. Accessed October 11, 2024.
31. Hughes JR, Parsons JL. FLASH radiotherapy: Current Knowledge and Future Insights Using Proton-Beam Therapy. *Int J Mol Sci*. 2020;21(18):6492. Published 2020 Sep 5. doi:10.3390/ijms21186492
32. Cancer Care Alberta Proton Therapy Guideline Advisory Group. Proton beam radiation therapy: Clinical Practice Guideline RT-002 – Version 3.  
<https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-rt002-proton-beam-RT.pdf>. Updated October 27, 2023. Accessed October 11, 2024.
33. Singer RJ, Ogilvy CS, Rordorf G. Brain arteriovenous malformations. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated March 12, 2024. Accessed October 10, 2024.
34. Kobeissi JM, Hilal L, Simone CB 2nd, Lin H, Crane CH, Hajj C. Proton Therapy in the Management of Hepatocellular Carcinoma. *Cancers (Basel)*. 2022;14(12):2900. Published 2022 Jun 12. doi:10.3390/cancers14122900
35. Stenson KM, Haraf DJ. Paranasal sinus cancer. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated May 08, 2024. Accessed October 10, 2024.
36. Zenonos GA. C. Chordoma of the skull base. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated August 01, 2024. Accessed October 11, 2024.
37. Douglas JG, Koh WJ, Austin-Seymour M, Laramore GE. Treatment of salivary gland neoplasms with fast neutron radiotherapy. *Arch Otolaryngol Head Neck Surg*. 2003;129(9):944-948. doi:10.1001/archotol.129.9.944
38. Local coverage determination: proton beam therapy (L36658). Centers for Medicare and Medicaid Services Web site. <http://www.cms.hhs.gov/mcd/search.asp>. Published October 24, 2016 (revised October 03, 2024). Accessed October 10, 2024.
39. Shih HA, Rengan R, Apisarnthanarax S, et al. ACR-ASTRO Practice Parameter for the Performance of Proton Beam Radiation Therapy. *Am J Clin Oncol*. 2020;43(3):149-159. doi:10.1097/COC.0000000000000672
40. Frank SJ, Das IJ, Simone CB 2nd, et al. ACR-ARS Practice Parameter for the Performance of Proton Beam Therapy. *Int J Part Ther*. 2024;13:100021. Published 2024 Apr 25. doi:10.1016/j.ijpt.2024.100021
41. Zeng J, Badiyan SN, Garces YI, et al. Consensus Statement on Proton Therapy in Mesothelioma. *Pract Radiat Oncol*. 2021;11(2):119-133. doi:10.1016/j.prro.2020.05.004
42. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology. Mesothelioma: pleural (Version 2.2024).  
[https://www.nccn.org/professionals/physician\\_gls/pdf/meso\\_pleural.pdf](https://www.nccn.org/professionals/physician_gls/pdf/meso_pleural.pdf). Published October 04, 2024. Accessed October 16, 2024.

43. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology. Pediatric central nervous system cancers (Version 1.2024).  
[https://www.nccn.org/professionals/physician\\_gls/pdf/ped\\_cns.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ped_cns.pdf). Published February 26, 2024. Accessed October 16, 2024.
44. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology. Pediatric hodgkin lymphoma (Version 1.2024).  
[https://www.nccn.org/professionals/physician\\_gls/pdf/ped\\_hodgkin.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ped_hodgkin.pdf). Published May 14, 2024. Accessed October 16, 2024.

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

©2024 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.